Fibrinogen Concentrate Safely Replaces Cryoprecipitate in Neonatal Cardiac Surgery
Anesthesia and Analgesia shared an insightful post on LinkedIn:
“When compared to cryoprecipitate, can fibrinogen concentrate adequately restore hemostasis and reduce postoperative thrombosis risk in neonates undergoing cardiac surgery with cardiopulmonary bypass (CPB)?
Patients who received fibrinogen concentrate CPB had similar ex vivo clot degradation rates throughout the immediate perioperative period with greater degradation at 24 hours postoperatively and received less post-CPB blood products with no increased risk of bleeding or thrombotic complications when compared to patients who received cryoprecipitate.
Given the increased risks associated with allogenic blood transfusions, our results suggest that fibrinogen concentrate may be a suitable alternative to achieve perioperative hemostasis in neonates undergoing cardiac surgery without increased risk of thrombotic or bleeding complications.”
Read the full article here.
Article: Effect of In Vivo Administration of Fibrinogen Concentrate Versus Cryoprecipitate on Ex Vivo Clot Degradation in Neonates Undergoing Cardiac Surgery
Authors: Laura A. Downey, Nina Moiseiwitsch, Kimberly Nellenbach, Yijin Xiang, Ashley C. Brown, Nina A.
Stay updated on the latest scientific advances in the field of clotting disorders with Hemostasis Today.
-
Mar 11, 2026, 18:27Cesar Garrido and Lackram Bodoe Are Advancing WFH Partnerships in Trinidad and Tobago
-
Mar 11, 2026, 18:14Aloke Finn: Silent Plaque Rupture and Healing in Coronary Artery Disease
-
Mar 11, 2026, 17:23Mattia Galli: A Privilege to Collaborate on Such a Complex Topic as Cardio-Rheumatology
-
Mar 11, 2026, 17:12Shubham Misra: Proteomic Biomarkers for Acute Stroke Subtype Classification
-
Mar 11, 2026, 16:55Melanie Daniel: Modeling High-Purity von Willebrand Factor for Individualized Dosing in Surgery
-
Mar 11, 2026, 15:46Bleeding and Thrombosis Outcomes in Older Patients With Myelodysplastic Syndromes – JTH
-
Mar 11, 2026, 15:37Sonia Muliyil: The Greatest Benefit is The Wellbeing and Sustenance of Half The World’s Population
-
Mar 11, 2026, 15:34Kymentie Ferdinande: Rivaroxaban in Cirrhosis and the Path Toward Individualized Anticoagulation
-
Mar 11, 2026, 15:34Sheharyar Raza: When More Testing Isn’t Always Better in Healthy Donor Screening